Ionis Pharmaceuticals Inc Asset Resilience Ratio
Ionis Pharmaceuticals Inc asset resilience ratio. Ionis Pharmaceuticals Inc (IONS) has an Asset Resilience Ratio of 56.92% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IONS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ionis Pharmaceuticals Inc (1999–2025)
Asset resilience ratio of Ionis Pharmaceuticals Inc from 1999 to 2025. This chart shows how Ionis Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Ionis Pharmaceuticals Inc (IONS) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ionis Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IONS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.70 Billion | 56.92% |
| Total Liquid Assets | $1.70 Billion | 56.92% |
Asset Resilience Insights
- Very High Liquidity: Ionis Pharmaceuticals Inc maintains exceptional liquid asset reserves at 56.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ionis Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Ionis Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Ionis Pharmaceuticals Inc Asset Resilience Ratio by Year (1999–2025)
Ionis Pharmaceuticals Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Ionis Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.42% | $2.31 Billion | $3.52 Billion | -3.02pp |
| 2024-12-31 | 68.44% | $2.06 Billion | $3.00 Billion | +3.82pp |
| 2023-12-31 | 64.61% | $1.93 Billion | $2.99 Billion | -3.31pp |
| 2022-12-31 | 67.92% | $1.72 Billion | $2.53 Billion | +20.22pp |
| 2021-12-31 | 47.69% | $1.25 Billion | $2.61 Billion | -14.85pp |
| 2020-12-31 | 62.54% | $1.49 Billion | $2.39 Billion | +6.36pp |
| 2019-12-31 | 56.18% | $1.82 Billion | $3.23 Billion | -11.49pp |
| 2018-12-31 | 67.67% | $1.81 Billion | $2.67 Billion | +0.11pp |
| 2017-12-31 | 67.55% | $893.09 Million | $1.32 Billion | +67.29pp |
| 2016-12-31 | 0.26% | $2.41 Million | $912.47 Million | -2.33pp |
| 2015-12-31 | 2.59% | $24.79 Million | $956.11 Million | -5.97pp |
| 2014-12-31 | 8.57% | $81.88 Million | $955.81 Million | +2.42pp |
| 2013-12-31 | 6.15% | $52.10 Million | $847.16 Million | -0.01pp |
| 2012-12-31 | 6.16% | $33.62 Million | $545.69 Million | -51.21pp |
| 2011-12-31 | 57.37% | $278.19 Million | $484.89 Million | -15.71pp |
| 2010-12-31 | 73.08% | $402.30 Million | $550.48 Million | +1.71pp |
| 2009-12-31 | 71.37% | $469.06 Million | $657.18 Million | +23.81pp |
| 2008-12-31 | 47.56% | $273.08 Million | $574.15 Million | +26.27pp |
| 2007-12-31 | 21.29% | $55.10 Million | $258.86 Million | -9.51pp |
| 2006-12-31 | 30.80% | $78.82 Million | $255.91 Million | -23.74pp |
| 2005-12-31 | 54.54% | $90.74 Million | $166.37 Million | +17.77pp |
| 2004-12-31 | 36.77% | $76.63 Million | $208.43 Million | -17.69pp |
| 2003-12-31 | 54.45% | $182.39 Million | $334.94 Million | +11.71pp |
| 2002-12-31 | 42.74% | $187.50 Million | $438.68 Million | -1.62pp |
| 2001-12-31 | 44.36% | $185.01 Million | $417.06 Million | -3.47pp |
| 2000-12-31 | 47.83% | $87.65 Million | $183.26 Million | +30.85pp |
| 1999-12-31 | 16.97% | $17.50 Million | $103.11 Million | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more